0
Red · act now
2
Amber · monitor
3
Green · opportunity
Amber alerts: monitor
Amber Evidence: ADA position · November 2026
Charcoal toothpaste category continues without ADA Seal recognition or safety consensus

The charcoal toothpaste category continues without ADA Seal recognition or a safety consensus. Continuing consumer coverage traces to the ADA's standing position, not to any new statement or Seal decision. Ongoing consumer demand keeps reputational exposure live for any client product in this space.

Monitor ADA position
Amber Regulatory: FDA status · November 2026
Hydroxyapatite toothpaste remains unapproved for anti-caries claims in the US

As of an April 2026 review, FDA still regulates toothpaste as a cosmetic product and has not approved hydroxyapatite toothpaste for anti-caries claims. Claims drafted for EU or Japan markets cannot be reused domestically without regulatory risk. The professional chairside story (CDT D2991) is now separate; see green signals.

Consumer search and social signals also inform velocity rating.

Monitor FDA docket
Green signals: opportunities
Opportunity Reimbursement: CDT code · November 2026
CDT D2991 gives chairside hydroxyapatite regeneration a billing code

CDT code D2991, in effect since 2024, lets dentists bill for chairside hydroxyapatite-regeneration scaffold treatment, such as Curodont Repair and CrystLCare, on incipient lesions. This is a professional, reimbursable in-office treatment, distinct from consumer nHAp toothpaste, and it is moving ahead of the stalled FDA claims question.

Consumer search and social signals also inform velocity rating.

Opportunity Commercial: PAP whitening · November 2026
PAP+ whitening adoption is broadening across DTC brands

PAP+ whitening adoption is broadening across DTC brands with no adverse safety signal identified to date. No material new clinical evidence surfaced this cycle; general market data supports continued category growth.

Consumer search and social signals also inform velocity rating.

Opportunity Clinical: hydroxyapatite · November 2026
Active US trials are building the hydroxyapatite evidence base

Active US clinical trials on hydroxyapatite remineralization and dentin hypersensitivity are underway, building the evidence base needed for future claims. The listing was not re-confirmed this cycle.

Consumer search and social signals also inform velocity rating.

"In oral health, the evidence narrative is not just a regulatory requirement — it is the brand. Brands that build clinical credibility now are building the moat that protects them for a decade."

Schedule a consultation →